Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-[methyl-(5-geranyl-4-methyl-pent-3-enyl)-amino]-ethyl-diphosphate is an experimental small molecule and organophosphate compound. It is a synthetic analog of geranylgeranyl diphosphate, designed to interact with protein prenyltransferases such as farnesyltransferase and geranylgeranyltransferase type I. These enzymes catalyze the transfer of prenyl groups to target proteins, a key step in post-translational modification that affects protein localization and function. The compound has been studied primarily for its potential to modulate or inhibit these enzymes, which are implicated in oncogenic signaling pathways due to their role in modifying small GTPases like Ras and Rho family proteins[1][5][9]. There are no approved indications or marketed products containing this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[methyl-(5-geranyl-4-methyl-pent-3-enyl)-amino]-ethyl-diphosphate.